Syncona leads CHF35M A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC)

Read the full 357 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE